Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E7016 + temozolomide
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
E7016 is an orally active poly(ADP-ribose) polymerase (PARP) inhibitor that enhances tumor cell radiosensitivity by inhibiting DNA repair. When combined with temozolomide, an oral alkylating agent used primarily to treat glioblastoma multiforme and anaplastic astrocytoma, the combination has shown greater than additive effects in preclinical models, particularly in enhancing the efficacy of radiotherapy for brain tumors. Temozolomide works by damaging DNA in cancer cells, preventing their replication and growth. The combination is being investigated as a potential therapy to improve outcomes for patients with glioblastoma multiforme and other advanced solid tumors[1][2][3][4][5][7].
- Other names
- E7016 + temozolomide
02
Targets
DNA
Beyond the preview
Go deeper on E7016 + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E7016 + temozolomide.